YU36401A - Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem - Google Patents

Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem

Info

Publication number
YU36401A
YU36401A YU36401A YU36401A YU36401A YU 36401 A YU36401 A YU 36401A YU 36401 A YU36401 A YU 36401A YU 36401 A YU36401 A YU 36401A YU 36401 A YU36401 A YU 36401A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical composition
modified insulin
insulin sensitiser
composition
stimulator
Prior art date
Application number
YU36401A
Other languages
English (en)
Inventor
Robert Glinecke
Susan Marie Milosovich
William Muldon
Vincenzo Re
Joseph Sauer
Janet Louse Skinner
Original Assignee
Smithlkine Beecham P.L.C.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithlkine Beecham P.L.C., Smithkline Beecham Corporation filed Critical Smithlkine Beecham P.L.C.
Publication of YU36401A publication Critical patent/YU36401A/sh
Publication of RS50208B publication Critical patent/RS50208B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Farmaceutska kompozicija koja sadrži jedan stimulator osetljivosti na insulin i njegov farmaceutski prihvatljiv nosač, pri čemu je ta kompozicija tako podešena da omogućava modifikovano ispuštanje stimulatora osetljivosti na insulin i upotrebu takve kompozicije u medicini.
YU36401A 1998-11-12 1999-11-12 Višeslojna tableta sa kombinovanim oslobađanjem aktivne supstance RS50208B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (2)

Publication Number Publication Date
YU36401A true YU36401A (sh) 2004-05-12
RS50208B RS50208B (sr) 2009-07-15

Family

ID=26314667

Country Status (39)

Country Link
EP (3) EP1917962A1 (sh)
JP (1) JP2002529505A (sh)
KR (2) KR20060097140A (sh)
CN (1) CN1289081C (sh)
AP (2) AP2008004490A0 (sh)
AR (2) AR023699A1 (sh)
AT (1) ATE382352T1 (sh)
AU (1) AU768578B2 (sh)
BG (2) BG109893A (sh)
BR (1) BR9915215A (sh)
CA (1) CA2350659C (sh)
CO (1) CO5190673A1 (sh)
CY (1) CY1107909T1 (sh)
CZ (1) CZ20011628A3 (sh)
DE (1) DE69937898T2 (sh)
DK (1) DK1128827T3 (sh)
DZ (1) DZ2937A1 (sh)
EA (3) EA200702648A1 (sh)
EG (2) EG22344A (sh)
ES (1) ES2299269T3 (sh)
HK (1) HK1040909B (sh)
HR (2) HRP20010342B1 (sh)
HU (1) HUP0104307A3 (sh)
ID (1) ID29344A (sh)
IL (2) IL143003A0 (sh)
MY (1) MY135973A (sh)
NO (1) NO20012351L (sh)
NZ (2) NZ511611A (sh)
OA (1) OA11676A (sh)
PE (1) PE20001428A1 (sh)
PL (1) PL198717B1 (sh)
PT (1) PT1128827E (sh)
RS (1) RS50208B (sh)
SI (1) SI1128827T1 (sh)
SK (1) SK286937B6 (sh)
TR (2) TR200503846T2 (sh)
TW (2) TWI257305B (sh)
UY (2) UY25798A1 (sh)
WO (1) WO2000028990A1 (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
ATE380022T1 (de) * 2001-01-31 2007-12-15 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
JP2005514399A (ja) * 2001-12-21 2005-05-19 スミスクライン ビーチャム コーポレーション ＰＰＡＲγアクチベーターの投薬法
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
WO2004006921A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
CA2514879C (en) 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
NZ541749A (en) 2003-01-29 2009-06-26 Takeda Pharmaceutical Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
WO2013010137A2 (en) * 2011-07-14 2013-01-17 Jacks Health Technologies Llc A composition, device and method for delayed and sustained release of brain energy molecules
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1992000967A1 (fr) 1990-07-03 1992-01-23 Yamanouchi Pharmaceutical Co., Ltd. Compose biheterocyclique
US5334604A (en) 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
AU1743292A (en) 1991-04-11 1992-11-17 Takeda Chemical Industries Ltd. Thiazolidinedione derivatives, production and use thereof
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (sh) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
EP0635007A1 (en) 1992-04-10 1995-01-25 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
PL176885B1 (pl) 1992-07-03 1999-08-31 Smithkline Beecham Plc Kompozycja farmaceutyczna
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
EP1019049A1 (en) * 1997-03-24 2000-07-19 Galderma Research & Development, S.N.C. Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (niddm) using specific retinoid compounds

Also Published As

Publication number Publication date
DE69937898T2 (de) 2009-01-02
PT1128827E (pt) 2008-03-10
NO20012351L (no) 2001-07-04
EG22344A (en) 2002-12-31
UY25800A1 (es) 2000-08-21
KR20010073229A (ko) 2001-07-31
NZ511611A (en) 2003-10-31
MY135973A (en) 2008-07-31
PL198717B1 (pl) 2008-07-31
DZ2937A1 (fr) 2004-03-15
WO2000028990A1 (en) 2000-05-25
EP1128827A1 (en) 2001-09-05
HK1040909B (zh) 2008-08-01
PE20001428A1 (es) 2001-02-08
HK1040909A1 (en) 2002-06-28
CN1289081C (zh) 2006-12-13
TR200101337T2 (tr) 2001-11-21
AP1901A (en) 2008-10-24
CA2350659A1 (en) 2000-05-25
RS50208B (sr) 2009-07-15
CY1107909T1 (el) 2013-09-04
AR023700A1 (es) 2002-09-04
JP2002529505A (ja) 2002-09-10
NZ526440A (en) 2005-01-28
KR20060097140A (ko) 2006-09-13
UY25798A1 (es) 2000-12-29
CZ20011628A3 (cs) 2001-12-12
BG109893A (bg) 2008-11-28
AU768578B2 (en) 2003-12-18
PL348153A1 (en) 2002-05-06
KR100732599B1 (ko) 2007-06-27
OA11676A (en) 2005-01-12
HRP20010342B1 (en) 2008-04-30
SK6432001A3 (en) 2001-12-03
CO5190673A1 (es) 2002-08-29
NO20012351D0 (no) 2001-05-11
ES2299269T3 (es) 2008-05-16
BG105570A (en) 2002-02-28
SI1128827T1 (sl) 2008-06-30
BR9915215A (pt) 2001-07-31
AR023699A1 (es) 2002-09-04
ID29344A (id) 2001-08-23
EA200601144A1 (ru) 2007-02-27
TR200503846T2 (tr) 2007-01-22
EG24463A (en) 2009-07-16
HRP20010342A2 (en) 2002-06-30
SK286937B6 (sk) 2009-07-06
TWI246920B (en) 2006-01-11
CA2350659C (en) 2009-06-09
DK1128827T3 (da) 2008-04-28
HRP20080117A2 (en) 2008-10-31
IL183972A0 (en) 2007-10-31
ATE382352T1 (de) 2008-01-15
EP1128827B1 (en) 2008-01-02
BG65444B1 (bg) 2008-08-29
EA200702648A1 (ru) 2008-10-30
EP1815855A1 (en) 2007-08-08
HUP0104307A2 (hu) 2002-07-29
EP1917962A1 (en) 2008-05-07
EA200100540A1 (ru) 2001-10-22
DE69937898D1 (de) 2008-02-14
TW200505436A (en) 2005-02-16
HUP0104307A3 (en) 2003-12-29
EA007608B1 (ru) 2006-12-29
AU1272900A (en) 2000-06-05
IL143003A0 (en) 2002-04-21
CN1333683A (zh) 2002-01-30
TWI257305B (en) 2006-07-01
AP2008004490A0 (en) 2008-06-30

Similar Documents

Publication Publication Date Title
HRP20080117A2 (en) Pharmaceutical composition for modified release insulin sensitiser
MY124695A (en) Novel composition and use.
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
ATE401892T1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
GEP20033027B (en) Use of Substituted Benzopyran Analogs for Treatment of Inflammation
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
AR027059A1 (es) Bases de mannich indolicas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para la preparacion de medicamentos
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
ATE292453T1 (de) Antivirale arznei
BR0012901A (pt) Medicamentos de ß - carbolina
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
AU2002223970A1 (en) Kyberdrug as autovaccines with immune-regulating effects
AR019331A2 (es) Composicion farmaceutica que contiene un sensibilizador a insulina y un secretagogo de insulina.
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
DE69830305D1 (de) Ortsspezifische arzneimittel verabreichung
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
DE59501945D1 (de) Orale Arzeimittelzubereitung enthaltend Diclofenac-Natrium und eine organische Säure
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.